首页 > 最新文献

Journal of Diabetes最新文献

英文 中文
“Path of the Heart” (The BPROAD Study) Addresses Optimal Systolic Blood Pressure for Patients With Diabetes
IF 3 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-23 DOI: 10.1111/1753-0407.70053
Ning Guang
<p>Awaiting my presentation at the centennial gathering of the American Heart Association (AHA) in Chicago, I opened my diary once again, particularly the one dated February 23, 2019, which reads, “After two years of meticulous preparation, the Path of the Heart research initiative has finally commenced.” The Path of the Heart refers to the BPROAD study, which has garnered significant acclaim due to its presentation at the Late-Breaking Science session of the AHA and concurrent publication in the prestigious <i>New England Journal of Medicine</i> [<span>1</span>]. Yet, few are acquainted with the trepidation that marked the inception of this endeavor 5 years prior, the indecision that lingered during the 2-year preparation phase, or the challenges posed by the COVID-19 pandemic throughout the study's execution. I extend my profound admiration and gratitude to the team led by Prof. Wang Weiqing, with Bi Yufang, Xu Yu, and Li Mian at the helm of the core research group, for their indomitable spirit and the resounding success of the study.</p><p>Hypertension affects 23.2% of the adult Chinese population, with a staggering half of diabetes patients also suffering from hypertension. Hypertension has emerged as the preeminent cause of mortality and disability among diabetes. Consequently, blood pressure management has become equally as imperative as glycemic control in the therapeutic strategies for diabetes in China. However, the optimal target for blood pressure reduction remains elusive. While the SPRINT study demonstrated a significant reduction in cardiovascular events with systolic blood pressure below 120 mmHg in hypertensive patients without diabetes [<span>2, 3</span>], the ACCORD study failed to observe similar benefits in diabetes patients. Besides, the ACCORD study was a 2 × 2 factorial-design study examining both blood pressure and glucose control [<span>4</span>]. Therefore, the target for blood pressure reduction in diabetes patients has become an unresolved issue, casting a shadow of confusion over clinical practice.</p><p>In light of this, the team led by Wang Weiqing and Bi Yufang from Ruijin Hospital has spearheaded the BPROAD study [<span>5, 6</span>]. This nationwide, multicenter, open-label, parallel-group, randomized controlled clinical trial made its debut as the opening presentation at the 2024 AHA Scientific Session, marking a historic milestone for Chinese researchers in the field of cardiovascular and metabolic clinical research.</p><p>The BPROAD study has established that intensive blood pressure management targeting a systolic blood pressure below 120 mmHg, as opposed to conventional management aiming for below 140 mmHg, results in a 21% reduction in the primary composite endpoint of major cardiovascular events, including non-fatal stroke, non-fatal myocardial infarction, heart failure requiring treatment or hospitalization, and cardiovascular death, in type 2 diabetes patients with elevated systolic blood pressure and inc
{"title":"“Path of the Heart” (The BPROAD Study) Addresses Optimal Systolic Blood Pressure for Patients With Diabetes","authors":"Ning Guang","doi":"10.1111/1753-0407.70053","DOIUrl":"10.1111/1753-0407.70053","url":null,"abstract":"&lt;p&gt;Awaiting my presentation at the centennial gathering of the American Heart Association (AHA) in Chicago, I opened my diary once again, particularly the one dated February 23, 2019, which reads, “After two years of meticulous preparation, the Path of the Heart research initiative has finally commenced.” The Path of the Heart refers to the BPROAD study, which has garnered significant acclaim due to its presentation at the Late-Breaking Science session of the AHA and concurrent publication in the prestigious &lt;i&gt;New England Journal of Medicine&lt;/i&gt; [&lt;span&gt;1&lt;/span&gt;]. Yet, few are acquainted with the trepidation that marked the inception of this endeavor 5 years prior, the indecision that lingered during the 2-year preparation phase, or the challenges posed by the COVID-19 pandemic throughout the study's execution. I extend my profound admiration and gratitude to the team led by Prof. Wang Weiqing, with Bi Yufang, Xu Yu, and Li Mian at the helm of the core research group, for their indomitable spirit and the resounding success of the study.&lt;/p&gt;&lt;p&gt;Hypertension affects 23.2% of the adult Chinese population, with a staggering half of diabetes patients also suffering from hypertension. Hypertension has emerged as the preeminent cause of mortality and disability among diabetes. Consequently, blood pressure management has become equally as imperative as glycemic control in the therapeutic strategies for diabetes in China. However, the optimal target for blood pressure reduction remains elusive. While the SPRINT study demonstrated a significant reduction in cardiovascular events with systolic blood pressure below 120 mmHg in hypertensive patients without diabetes [&lt;span&gt;2, 3&lt;/span&gt;], the ACCORD study failed to observe similar benefits in diabetes patients. Besides, the ACCORD study was a 2 × 2 factorial-design study examining both blood pressure and glucose control [&lt;span&gt;4&lt;/span&gt;]. Therefore, the target for blood pressure reduction in diabetes patients has become an unresolved issue, casting a shadow of confusion over clinical practice.&lt;/p&gt;&lt;p&gt;In light of this, the team led by Wang Weiqing and Bi Yufang from Ruijin Hospital has spearheaded the BPROAD study [&lt;span&gt;5, 6&lt;/span&gt;]. This nationwide, multicenter, open-label, parallel-group, randomized controlled clinical trial made its debut as the opening presentation at the 2024 AHA Scientific Session, marking a historic milestone for Chinese researchers in the field of cardiovascular and metabolic clinical research.&lt;/p&gt;&lt;p&gt;The BPROAD study has established that intensive blood pressure management targeting a systolic blood pressure below 120 mmHg, as opposed to conventional management aiming for below 140 mmHg, results in a 21% reduction in the primary composite endpoint of major cardiovascular events, including non-fatal stroke, non-fatal myocardial infarction, heart failure requiring treatment or hospitalization, and cardiovascular death, in type 2 diabetes patients with elevated systolic blood pressure and inc","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Linking Creatinine-to-Body Weight Ratio With Diabetes Incidence: A Multiethnic Malaysian Cohort Study
IF 3 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-22 DOI: 10.1111/1753-0407.70039
Noraidatulakma Abdullah, Ying-Xian Goh, Aisyatul Najihah Khuzaimi, Azwa Shawani Kamalul Arifin, Nurul Ain Mhd Yusuf, Nazihah Abd Jalal, Norliza Ismail, Nurul Faeizah Husin, Mohd Arman Kamaruddin, Rahman Jamal

Background

Emerging evidence suggests that the creatinine-to-body weight (Cre/BW) ratio is a predictor for incident diabetes in the Asian population. This study examined the association between Cre/BW ratio and incident diabetes, as well as the relationship between Cre/BW ratio and skeletal muscle and body fat mass in a multiethnic Malaysian cohort.

Methods

A total of 13 047 eligible participants were selected from 119 560 The Malaysian Cohort participants. Of these, 750 who developed diabetes were selected as cases, while 3750 controls were chosen randomly from healthy participants. This nested case–control study included 4500 eligible participants from The Malaysian Cohort, with a 1:5 case-to-control ratio. Participants were stratified into four groups based on Cre/BW ratio quartiles. The Cox proportional hazards model evaluated the effect of Cre/BW ratio on developing incident diabetes. The association between Cre/BW ratio and body composition was assessed using the Pearson correlation coefficient.

Results

Of the 13 047 eligible participants followed up over 5.3 years, 5.75% (n = 750) developed diabetes. Diabetes incidence decreased with increasing Cre/BW ratios. The Cre/BW ratio was inversely correlated with diabetes risk (HR: 0.403, 95% CI: 0.315–0.515, p < 0.001). Additionally, males and Indians had a higher risk of developing incident diabetes. A significant correlation was observed between Cre/BW ratio and body fat mass (p < 0.001).

Conclusions

This study reveals an inverse association between the Cre/BW ratio and incident diabetes. It also found a significant moderate correlation between the Cre/BW ratio and body fat mass.

{"title":"Linking Creatinine-to-Body Weight Ratio With Diabetes Incidence: A Multiethnic Malaysian Cohort Study","authors":"Noraidatulakma Abdullah,&nbsp;Ying-Xian Goh,&nbsp;Aisyatul Najihah Khuzaimi,&nbsp;Azwa Shawani Kamalul Arifin,&nbsp;Nurul Ain Mhd Yusuf,&nbsp;Nazihah Abd Jalal,&nbsp;Norliza Ismail,&nbsp;Nurul Faeizah Husin,&nbsp;Mohd Arman Kamaruddin,&nbsp;Rahman Jamal","doi":"10.1111/1753-0407.70039","DOIUrl":"10.1111/1753-0407.70039","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Emerging evidence suggests that the creatinine-to-body weight (Cre/BW) ratio is a predictor for incident diabetes in the Asian population. This study examined the association between Cre/BW ratio and incident diabetes, as well as the relationship between Cre/BW ratio and skeletal muscle and body fat mass in a multiethnic Malaysian cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 13 047 eligible participants were selected from 119 560 The Malaysian Cohort participants. Of these, 750 who developed diabetes were selected as cases, while 3750 controls were chosen randomly from healthy participants. This nested case–control study included 4500 eligible participants from The Malaysian Cohort, with a 1:5 case-to-control ratio. Participants were stratified into four groups based on Cre/BW ratio quartiles. The Cox proportional hazards model evaluated the effect of Cre/BW ratio on developing incident diabetes. The association between Cre/BW ratio and body composition was assessed using the Pearson correlation coefficient.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 13 047 eligible participants followed up over 5.3 years, 5.75% (<i>n</i> = 750) developed diabetes. Diabetes incidence decreased with increasing Cre/BW ratios. The Cre/BW ratio was inversely correlated with diabetes risk (HR: 0.403, 95% CI: 0.315–0.515, <i>p</i> &lt; 0.001). Additionally, males and Indians had a higher risk of developing incident diabetes. A significant correlation was observed between Cre/BW ratio and body fat mass (<i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study reveals an inverse association between the Cre/BW ratio and incident diabetes. It also found a significant moderate correlation between the Cre/BW ratio and body fat mass.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143021353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overcoming Missing Data: Accurately Predicting Cardiovascular Risk in Type 2 Diabetes, A Systematic Review
IF 3 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-22 DOI: 10.1111/1753-0407.70049
Wenhui Ren, Keyu Fan, Zheng Liu, Yanqiu Wu, Haiyan An, Huixin Liu

Understanding is limited regarding strategies for addressing missing value when developing and validating models to predict cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM). This study aimed to investigate the presence of and approaches to missing data in these prediction models. The MEDLINE electronic database was systematically searched for English-language studies from inception to June 30, 2024. The percentages of missing values, missingness mechanisms, and missing data handling strategies in the included studies were extracted and summarized. This study included 51 articles published between 2001 and 2024, involving 19 studies that focused solely on prediction model development, and 16 and 16 studies that incorporated internal and external validation, respectively. Most articles reported missing data in the development (n = 40/51) and external validation (n = 12/16) stages. Furthermore, the missing data were addressed in 74.5% of development studies and 68.8% of validation studies. Imputation emerged as the predominant method employed for both development (27/40) and validation (7/12) purposes, followed by deletion (17/40 and 4/12, respectively). During the model development phase, the number of studies reported missing data increased from 9 out of 15 before 2016 to 31 out of 36 in 2016 and subsequent years. Although missing values have received much attention in CVD risk prediction models in patients with T2DM, most studies lack adequate reporting on the methodologies used for addressing the missing data. Enhancing the quality assurance of prediction models necessitates heightened clarity and the utilization of suitable methodologies to handle missing data effectively.

{"title":"Overcoming Missing Data: Accurately Predicting Cardiovascular Risk in Type 2 Diabetes, A Systematic Review","authors":"Wenhui Ren,&nbsp;Keyu Fan,&nbsp;Zheng Liu,&nbsp;Yanqiu Wu,&nbsp;Haiyan An,&nbsp;Huixin Liu","doi":"10.1111/1753-0407.70049","DOIUrl":"10.1111/1753-0407.70049","url":null,"abstract":"<p>Understanding is limited regarding strategies for addressing missing value when developing and validating models to predict cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM). This study aimed to investigate the presence of and approaches to missing data in these prediction models. The MEDLINE electronic database was systematically searched for English-language studies from inception to June 30, 2024. The percentages of missing values, missingness mechanisms, and missing data handling strategies in the included studies were extracted and summarized. This study included 51 articles published between 2001 and 2024, involving 19 studies that focused solely on prediction model development, and 16 and 16 studies that incorporated internal and external validation, respectively. Most articles reported missing data in the development (<i>n</i> = 40/51) and external validation (<i>n</i> = 12/16) stages. Furthermore, the missing data were addressed in 74.5% of development studies and 68.8% of validation studies. Imputation emerged as the predominant method employed for both development (27/40) and validation (7/12) purposes, followed by deletion (17/40 and 4/12, respectively). During the model development phase, the number of studies reported missing data increased from 9 out of 15 before 2016 to 31 out of 36 in 2016 and subsequent years. Although missing values have received much attention in CVD risk prediction models in patients with T2DM, most studies lack adequate reporting on the methodologies used for addressing the missing data. Enhancing the quality assurance of prediction models necessitates heightened clarity and the utilization of suitable methodologies to handle missing data effectively.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143021357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brain Iron Deposition Alterations in Type 2 Diabetes Mellitus Patients With Mild Cognitive Impairment Based on Quantitative Susceptibility Mapping
IF 3 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-22 DOI: 10.1111/1753-0407.70052
Qiuyue Zhao, Subinuer Maimaitiaili, Yan Bi, Ming Li, Xin Li, Qian Li, Xinyi Shen, Min Wu, Linqing Fu, Zhengyang Zhu, Xin Zhang, Jiu Chen, Anning Hu, Zhou Zhang, Wen Zhang, Bing Zhang

Background

Iron is one of the most important elements in brain that may has a direct impact on the stability of central nervous system. The current study devoted to explore the alterations of iron distribution across the whole brain in type 2 diabetes mellitus (T2DM) patients with mild cognitive impairment (MCI).

Methods

The quantitative susceptibility mapping (QSM) technique was used to quantify the intracranial iron content of 74 T2DM patients with MCI and 86 T2DM patients with normal cognition (NC). The group comparison was performed by a voxel-based analysis. Then we evaluated the relationships between cognitive indicators and magnetic susceptibility value (MSV) measured by QSM of the significant brain areas, which were set as the regions of interest (ROIs). In addition, we analyzed the moderation effects of grey matter volume (GMV) of the related brain areas and several metabolic and cerebrovascular factors on the associations between MSV of ROIs and cognitive characteristics.

Results

T2DM patients with MCI exhibited a lower MSV in the right middle temporal gyrus (MTG) compared to NC group. And in the MCI group, there were significantly negative correlations between MSV of the right MTG and several memory indexes. Furthermore, the moderation effects of GMV of the whole brain and the bilateral MTG on the relationship between MSV of the right MTG and scores of list recognition were significant.

Conclusions

T2DM patients with MCI had a temporary decreased iron content in the right MTG, which may partially compensate for cognitive impairment.

Trial Registration: The study was registered at Clinicaltrials.gov (NCT02738671)

{"title":"Brain Iron Deposition Alterations in Type 2 Diabetes Mellitus Patients With Mild Cognitive Impairment Based on Quantitative Susceptibility Mapping","authors":"Qiuyue Zhao,&nbsp;Subinuer Maimaitiaili,&nbsp;Yan Bi,&nbsp;Ming Li,&nbsp;Xin Li,&nbsp;Qian Li,&nbsp;Xinyi Shen,&nbsp;Min Wu,&nbsp;Linqing Fu,&nbsp;Zhengyang Zhu,&nbsp;Xin Zhang,&nbsp;Jiu Chen,&nbsp;Anning Hu,&nbsp;Zhou Zhang,&nbsp;Wen Zhang,&nbsp;Bing Zhang","doi":"10.1111/1753-0407.70052","DOIUrl":"10.1111/1753-0407.70052","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Iron is one of the most important elements in brain that may has a direct impact on the stability of central nervous system. The current study devoted to explore the alterations of iron distribution across the whole brain in type 2 diabetes mellitus (T2DM) patients with mild cognitive impairment (MCI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The quantitative susceptibility mapping (QSM) technique was used to quantify the intracranial iron content of 74 T2DM patients with MCI and 86 T2DM patients with normal cognition (NC). The group comparison was performed by a voxel-based analysis. Then we evaluated the relationships between cognitive indicators and magnetic susceptibility value (MSV) measured by QSM of the significant brain areas, which were set as the regions of interest (ROIs). In addition, we analyzed the moderation effects of grey matter volume (GMV) of the related brain areas and several metabolic and cerebrovascular factors on the associations between MSV of ROIs and cognitive characteristics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>T2DM patients with MCI exhibited a lower MSV in the right middle temporal gyrus (MTG) compared to NC group. And in the MCI group, there were significantly negative correlations between MSV of the right MTG and several memory indexes. Furthermore, the moderation effects of GMV of the whole brain and the bilateral MTG on the relationship between MSV of the right MTG and scores of list recognition were significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>T2DM patients with MCI had a temporary decreased iron content in the right MTG, which may partially compensate for cognitive impairment.</p>\u0000 \u0000 <p><b>Trial Registration:</b> The study was registered at Clinicaltrials.gov (NCT02738671)</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143021393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Commentary on “Protective Effect of Regular Physical Activity Against Diabetes-Related Lower Extremity Amputation”
IF 3 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-22 DOI: 10.1111/1753-0407.70055
Zeinab Mohseni Afshar, Mohammad Barary, Arefeh Babazadeh, Fatemeh Rasulpur, Soheil Ebrahimpour
<p>We read with great interest the article titled “Protective effect of regular physical activity against diabetes-related lower extremity amputation,” published in your esteemed journal [<span>1</span>]. This study's objective—to evaluate the protective effects of appropriate and regular physical activity (PA) on the risk of lower extremity amputation (LEA) in individuals with diabetes—is both timely and relevant. We commend the authors for their valuable contributions to this critical area of research. However, certain study aspects warrant further discussion to enhance their scientific rigor and applicability.</p><p>First, the study did not incorporate specific laboratory parameters that could have strengthened its conclusions. Including biomarkers such as albumin, hemoglobin, thyroid and liver function tests, Vitamin D, Vitamin B12, Vitamin B3, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) would provide a more comprehensive understanding of the patients' risk profiles and the potential mechanisms linking PA to reduced LEA risk [<span>2</span>]. For instance, NLR and PLR are well-established predictors of mortality and complications in diabetic foot ulcers and could offer additional prognostic value.</p><p>Second, the study lacked detailed information regarding medications other than antidiabetic agents. Drugs such as antihypertensives and lipid-lowering therapies can significantly impact vascular health and diabetic outcomes. Without this data, it is challenging to isolate PA's protective effects fully.</p><p>Third, while the study considered some comorbidities, a broader exploration of underlying conditions is necessary. Comorbidities such as malignancies, psychological disorders, cerebrovascular diseases, bone deformities, diabetic retinopathy, and autoimmune diseases—in addition to diabetic neuropathy and peripheral artery disease (PAD)—may influence both PA participation and LEA risk [<span>3</span>]. Addressing these factors would provide a clearer understanding of the interactions between diabetes-related complications and PA.</p><p>Moreover, the study would benefit from additional demographic information, including educational level, urban versus rural residency, and history of previous diabetic ulcers. These variables are crucial as they can significantly influence diabetes management and adherence to PA regimens. Furthermore, there was no discussion regarding insulin resistance or the results of venous examinations, both pertinent to evaluating the risk of LEA.</p><p>In conclusion, while this study highlights the protective role of regular PA in preventing LEA among individuals with diabetes, addressing the limitations mentioned above would enhance its robustness and clinical relevance. Such considerations are critical for healthcare providers as they develop tailored strategies to improve patient outcomes. We hope the esteemed authors and editorial board will consider these constructive critiques and p
{"title":"Commentary on “Protective Effect of Regular Physical Activity Against Diabetes-Related Lower Extremity Amputation”","authors":"Zeinab Mohseni Afshar,&nbsp;Mohammad Barary,&nbsp;Arefeh Babazadeh,&nbsp;Fatemeh Rasulpur,&nbsp;Soheil Ebrahimpour","doi":"10.1111/1753-0407.70055","DOIUrl":"10.1111/1753-0407.70055","url":null,"abstract":"&lt;p&gt;We read with great interest the article titled “Protective effect of regular physical activity against diabetes-related lower extremity amputation,” published in your esteemed journal [&lt;span&gt;1&lt;/span&gt;]. This study's objective—to evaluate the protective effects of appropriate and regular physical activity (PA) on the risk of lower extremity amputation (LEA) in individuals with diabetes—is both timely and relevant. We commend the authors for their valuable contributions to this critical area of research. However, certain study aspects warrant further discussion to enhance their scientific rigor and applicability.&lt;/p&gt;&lt;p&gt;First, the study did not incorporate specific laboratory parameters that could have strengthened its conclusions. Including biomarkers such as albumin, hemoglobin, thyroid and liver function tests, Vitamin D, Vitamin B12, Vitamin B3, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) would provide a more comprehensive understanding of the patients' risk profiles and the potential mechanisms linking PA to reduced LEA risk [&lt;span&gt;2&lt;/span&gt;]. For instance, NLR and PLR are well-established predictors of mortality and complications in diabetic foot ulcers and could offer additional prognostic value.&lt;/p&gt;&lt;p&gt;Second, the study lacked detailed information regarding medications other than antidiabetic agents. Drugs such as antihypertensives and lipid-lowering therapies can significantly impact vascular health and diabetic outcomes. Without this data, it is challenging to isolate PA's protective effects fully.&lt;/p&gt;&lt;p&gt;Third, while the study considered some comorbidities, a broader exploration of underlying conditions is necessary. Comorbidities such as malignancies, psychological disorders, cerebrovascular diseases, bone deformities, diabetic retinopathy, and autoimmune diseases—in addition to diabetic neuropathy and peripheral artery disease (PAD)—may influence both PA participation and LEA risk [&lt;span&gt;3&lt;/span&gt;]. Addressing these factors would provide a clearer understanding of the interactions between diabetes-related complications and PA.&lt;/p&gt;&lt;p&gt;Moreover, the study would benefit from additional demographic information, including educational level, urban versus rural residency, and history of previous diabetic ulcers. These variables are crucial as they can significantly influence diabetes management and adherence to PA regimens. Furthermore, there was no discussion regarding insulin resistance or the results of venous examinations, both pertinent to evaluating the risk of LEA.&lt;/p&gt;&lt;p&gt;In conclusion, while this study highlights the protective role of regular PA in preventing LEA among individuals with diabetes, addressing the limitations mentioned above would enhance its robustness and clinical relevance. Such considerations are critical for healthcare providers as they develop tailored strategies to improve patient outcomes. We hope the esteemed authors and editorial board will consider these constructive critiques and p","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143021351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancements and Challenges in Immune Protection Strategies for Islet Transplantation 胰岛移植免疫保护策略的进展与挑战。
IF 3 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-20 DOI: 10.1111/1753-0407.70048
Xue Wang, Ziyuan Zeng, Dayan Li, Kai Wang, Wei Zhang, Yang Yu, Xi Wang

Pancreatic islet transplantation is a crucial treatment for managing type 1 diabetes (T1D) in clinical settings. However, the limited availability of human cadaveric islet donors and the need for ongoing administration of immunosuppressive agents post-transplantation hinder the widespread use of this treatment. Stem cell-derived islet organoids have emerged as an effective alternative to primary human islets. Nevertheless, implementing this cell replacement therapy still requires chronic immune suppression, which may result in life-long side effects. To address these challenges, innovations such as encapsulation devices, universal stem cells, and immunomodulatory strategies are being developed to mitigate immune rejection and prolong the function of the transplant. This review outlines the contemporary challenges in pancreatic β cell therapy, particularly immune rejection, and recent progress in immune-isolation devices, hypoimmunogenic stem cells, and immune regulation of transplants. A comprehensive evaluation of the advantages and limitations of these approaches will contribute to improved future clinical investigations. With these promising advancements, the application of pancreatic β cell therapy holds the potential to effectively treat T1D and benefit a larger population of T1D patients.

胰岛移植是治疗1型糖尿病(T1D)的关键治疗方法。然而,人类尸体胰岛供体的有限可用性和移植后持续使用免疫抑制剂的需要阻碍了这种治疗的广泛使用。干细胞衍生的类胰岛器官已成为替代原代人胰岛的有效方法。然而,实施这种细胞替代疗法仍然需要慢性免疫抑制,这可能导致终生的副作用。为了应对这些挑战,诸如封装装置、通用干细胞和免疫调节策略等创新正在开发中,以减轻免疫排斥反应并延长移植功能。这篇综述概述了当前胰岛β细胞治疗面临的挑战,特别是免疫排斥反应,以及免疫隔离装置、低免疫原性干细胞和移植免疫调节的最新进展。全面评估这些方法的优缺点将有助于改善未来的临床研究。有了这些有希望的进展,胰岛β细胞疗法的应用具有有效治疗T1D的潜力,并使更多的T1D患者受益。
{"title":"Advancements and Challenges in Immune Protection Strategies for Islet Transplantation","authors":"Xue Wang,&nbsp;Ziyuan Zeng,&nbsp;Dayan Li,&nbsp;Kai Wang,&nbsp;Wei Zhang,&nbsp;Yang Yu,&nbsp;Xi Wang","doi":"10.1111/1753-0407.70048","DOIUrl":"10.1111/1753-0407.70048","url":null,"abstract":"<p>Pancreatic islet transplantation is a crucial treatment for managing type 1 diabetes (T1D) in clinical settings. However, the limited availability of human cadaveric islet donors and the need for ongoing administration of immunosuppressive agents post-transplantation hinder the widespread use of this treatment. Stem cell-derived islet organoids have emerged as an effective alternative to primary human islets. Nevertheless, implementing this cell replacement therapy still requires chronic immune suppression, which may result in life-long side effects. To address these challenges, innovations such as encapsulation devices, universal stem cells, and immunomodulatory strategies are being developed to mitigate immune rejection and prolong the function of the transplant. This review outlines the contemporary challenges in pancreatic β cell therapy, particularly immune rejection, and recent progress in immune-isolation devices, hypoimmunogenic stem cells, and immune regulation of transplants. A comprehensive evaluation of the advantages and limitations of these approaches will contribute to improved future clinical investigations. With these promising advancements, the application of pancreatic β cell therapy holds the potential to effectively treat T1D and benefit a larger population of T1D patients.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations of Tea Consumption With the Risk of All-Cause and Cause-Specific Mortality Among Adults With Type 2 Diabetes: A Prospective Cohort Study in China 中国一项前瞻性队列研究:饮茶与成人2型糖尿病患者全因和特定原因死亡风险的关系
IF 3 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-20 DOI: 10.1111/1753-0407.70040
Lifeng Wang, Xikang Fan, Jian Su, Yu Qin, Zhongming Sun, Yan Lu, Shujun Gu, Chong Shen, Jinyi Zhou, Hao Yu, Ming Wu

Aims

To investigate the associations of tea consumption with all-cause and cause-specific mortality among type 2 diabetes mellitus (T2DM) Chinese patients.

Materials and Methods

The present study included 15 718 participants from the Comprehensive Research on the Prevention and Control of Diabetes between 2013 and 2014 in Jiangsu, China. Information on tea consumption (including frequency, amount, and duration) was collected at baseline using interviewer-administered questionnaires. Death data were identified by linkage to the Death Certificate System. Cox proportional hazard regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).

Results

During a median follow-up of 9.77 (9.69, 9.82) years, 3046 deaths were documented, including 922 from cardiovascular disease (CVD) and 736 from cancer. Compared with nonconsumers, regular tea consumption (≥ 3 times/week, 1 cup/day, > 30 years) was associated with reduced all-cause mortality risk in T2DM, with HRs (95% CIs) of 0.82 (0.74, 0.91), 0.80 (0.72, 0.89), and 0.77 (0.68, 0.86). For cardiovascular mortality, the HRs (95% CIs) were 0.79 (0.65, 0.96), 0.72 (0.59, 0.89), and 0.75 (0.60, 0.93). The exposure-response relationship suggested that consuming 4 g/day may offer the most evident health benefits.

Conclusions

Among Chinese T2DM patients, higher tea frequency and amount intake were associated with lower risk of all-cause and CVD mortality. It is suggested that consuming 4 g/day of tea could potentially serve as an intervention target. These findings suggest that tea consumption can be a part of a healthy diet for T2DM patients.

目的:探讨饮茶与中国2型糖尿病(T2DM)患者全因死亡率和病因特异性死亡率的关系。材料与方法:本研究纳入2013 - 2014年中国江苏省糖尿病防治综合研究的15 718名参与者。在基线时,使用访谈者管理的问卷收集饮茶信息(包括频率、数量和持续时间)。死亡数据通过与死亡证明系统的链接进行识别。采用Cox比例风险回归模型估计风险比(hr)和95%置信区间(ci)。结果:在9.77(9.69,9.82)年的中位随访期间,记录了3046例死亡,其中922例死于心血管疾病(CVD), 736例死于癌症。与非饮茶者相比,经常饮茶(≥3次/周,1杯/天,30岁以上)与T2DM患者全因死亡风险降低相关,hr (95% ci)分别为0.82(0.74,0.91)、0.80(0.72,0.89)和0.77(0.68,0.86)。心血管疾病死亡率的hr (95% ci)分别为0.79(0.65,0.96)、0.72(0.59,0.89)和0.75(0.60,0.93)。暴露-反应关系表明,每天摄入4克可能会提供最明显的健康益处。结论:在中国T2DM患者中,较高的饮茶频率和饮茶量与较低的全因死亡率和心血管疾病死亡率相关。建议每天饮用4克茶可能作为一个潜在的干预目标。这些发现表明,饮茶可以成为2型糖尿病患者健康饮食的一部分。
{"title":"Associations of Tea Consumption With the Risk of All-Cause and Cause-Specific Mortality Among Adults With Type 2 Diabetes: A Prospective Cohort Study in China","authors":"Lifeng Wang,&nbsp;Xikang Fan,&nbsp;Jian Su,&nbsp;Yu Qin,&nbsp;Zhongming Sun,&nbsp;Yan Lu,&nbsp;Shujun Gu,&nbsp;Chong Shen,&nbsp;Jinyi Zhou,&nbsp;Hao Yu,&nbsp;Ming Wu","doi":"10.1111/1753-0407.70040","DOIUrl":"10.1111/1753-0407.70040","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To investigate the associations of tea consumption with all-cause and cause-specific mortality among type 2 diabetes mellitus (T2DM) Chinese patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>The present study included 15 718 participants from the Comprehensive Research on the Prevention and Control of Diabetes between 2013 and 2014 in Jiangsu, China. Information on tea consumption (including frequency, amount, and duration) was collected at baseline using interviewer-administered questionnaires. Death data were identified by linkage to the Death Certificate System. Cox proportional hazard regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During a median follow-up of 9.77 (9.69, 9.82) years, 3046 deaths were documented, including 922 from cardiovascular disease (CVD) and 736 from cancer. Compared with nonconsumers, regular tea consumption (≥ 3 times/week, 1 cup/day, &gt; 30 years) was associated with reduced all-cause mortality risk in T2DM, with HRs (95% CIs) of 0.82 (0.74, 0.91), 0.80 (0.72, 0.89), and 0.77 (0.68, 0.86). For cardiovascular mortality, the HRs (95% CIs) were 0.79 (0.65, 0.96), 0.72 (0.59, 0.89), and 0.75 (0.60, 0.93). The exposure-response relationship suggested that consuming 4 g/day may offer the most evident health benefits.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Among Chinese T2DM patients, higher tea frequency and amount intake were associated with lower risk of all-cause and CVD mortality. It is suggested that consuming 4 g/day of tea could potentially serve as an intervention target. These findings suggest that tea consumption can be a part of a healthy diet for T2DM patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
B Lymphocyte—A Prognostic Indicator in Post-Acute Pancreatitis Diabetes Mellitus B淋巴细胞- a在急性胰腺炎后糖尿病中的预后指标。
IF 3 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-12 DOI: 10.1111/1753-0407.70047
Xiaoyan Lin, Xiaoling Li, Junsheng Wang, Huiheng Liu

Objective

To determine the value of lymphocyte subsets and granulocyte/monocyte surface markers in predicting the risk of post-acute pancreatitis diabetes (PPDM-A).

Methods

This study included 308 in patients with acute pancreatitis (AP). The markers of granulocytes and monocytes and lymphocyte subsets were detected by flow cytometry, and the fluorescence intensity, absolute count and percentage were obtained. Based on the occurrence of diabetes after AP, patients were divided into two groups: PPDM-A and PPNG-A (post-acute pancreatitis with normal glucose). Correlations between granulocyte and monocyte surface markers and lymphocyte subsets were analyzed. Binary logistic regression was used to analyze the potential influencing factors of PPDM-A.

Results

Compared with patients with PPNG-A, patients with PPDM-A tend to be younger (p < 0.001) and have a higher proportion of fatty liver, recurrent pancreatitis, and hyperlipidemic pancreatitis. The results of linear regression showed that B% was negatively correlated with MFI of HLA-DR on monocytes (R2 = 0.145, p < 0.001), B% was positively correlated with CD10NEUT% (R2 = 0.291, p < 0.001), and MFI of HLA-DR on monocytes was negatively correlated with CD10NEUT% (R2 = 0.457, p < 0.001). Multivariate logistic regression analysis revealed that age, serous effusion, fatty liver, recurrent pancreatitis, and B% were independent risk factors for the occurrence of PPDM-A.

Conclusion

Our study has first confirmed the correlation between PPDM-A and lymphocyte subsets and CD10NEUT%. Furthermore we indicated that age, fatty liver, serous effusion, recurrent AP, and B% were independent risk factors for PPDM-A. The mechanism of granulocyte and monocyte surface markers and B lymphocytes on PPDM-A is worthy of study. This would help clarify the pathogenesis of PPDM-A at the cellular level and potentially provide new strategies for immunotherapy and even disease prevention. [Correction added on 24 January 2025, after first online publication: the third subtitle in Abstract section has been changed to ‘Results’.]

目的:探讨淋巴细胞亚群和粒细胞/单核细胞表面标志物对急性胰腺炎后糖尿病(PPDM-A)发病风险的预测价值。方法:本研究纳入308例急性胰腺炎(AP)患者。流式细胞术检测粒细胞、单核细胞和淋巴细胞亚群的标志物,获得荧光强度、绝对计数和百分比。根据AP后糖尿病的发生情况,将患者分为PPDM-A组和PPNG-A组(血糖正常的急性胰腺炎后)。分析了粒细胞和单核细胞表面标记物与淋巴细胞亚群之间的相关性。采用二元logistic回归分析PPDM-A的潜在影响因素。方法:与PPNG-A患者相比,PPDM-A患者倾向于年轻化(p 2 = 0.145, p -NEUT%) (R2 = 0.291, p -NEUT% (R2 = 0.457, p)。结论:本研究首次证实PPDM-A与淋巴细胞亚群和CD10-NEUT%之间存在相关性。此外,我们指出年龄、脂肪肝、浆液积液、复发性AP和B%是PPDM-A的独立危险因素。粒细胞、单核细胞表面标志物和B淋巴细胞对PPDM-A的作用机制值得研究。这将有助于在细胞水平上阐明PPDM-A的发病机制,并可能为免疫治疗甚至疾病预防提供新的策略。
{"title":"B Lymphocyte—A Prognostic Indicator in Post-Acute Pancreatitis Diabetes Mellitus","authors":"Xiaoyan Lin,&nbsp;Xiaoling Li,&nbsp;Junsheng Wang,&nbsp;Huiheng Liu","doi":"10.1111/1753-0407.70047","DOIUrl":"10.1111/1753-0407.70047","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To determine the value of lymphocyte subsets and granulocyte/monocyte surface markers in predicting the risk of post-acute pancreatitis diabetes (PPDM-A).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study included 308 in patients with acute pancreatitis (AP). The markers of granulocytes and monocytes and lymphocyte subsets were detected by flow cytometry, and the fluorescence intensity, absolute count and percentage were obtained. Based on the occurrence of diabetes after AP, patients were divided into two groups: PPDM-A and PPNG-A (post-acute pancreatitis with normal glucose). Correlations between granulocyte and monocyte surface markers and lymphocyte subsets were analyzed. Binary logistic regression was used to analyze the potential influencing factors of PPDM-A.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared with patients with PPNG-A, patients with PPDM-A tend to be younger (<i>p</i> &lt; 0.001) and have a higher proportion of fatty liver, recurrent pancreatitis, and hyperlipidemic pancreatitis. The results of linear regression showed that B% was negatively correlated with MFI of HLA-DR on monocytes (<i>R</i><sup>2</sup> = 0.145, <i>p</i> &lt; 0.001), B% was positively correlated with CD10<sup>−</sup>NEUT% (<i>R</i><sup>2</sup> = 0.291, <i>p</i> &lt; 0.001), and MFI of HLA-DR on monocytes was negatively correlated with CD10<sup>−</sup>NEUT% (<i>R</i><sup>2</sup> = 0.457, <i>p</i> &lt; 0.001). Multivariate logistic regression analysis revealed that age, serous effusion, fatty liver, recurrent pancreatitis, and B% were independent risk factors for the occurrence of PPDM-A.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study has first confirmed the correlation between PPDM-A and lymphocyte subsets and CD10<sup>−</sup>NEUT%. Furthermore we indicated that age, fatty liver, serous effusion, recurrent AP, and B% were independent risk factors for PPDM-A. The mechanism of granulocyte and monocyte surface markers and B lymphocytes on PPDM-A is worthy of study. This would help clarify the pathogenesis of PPDM-A at the cellular level and potentially provide new strategies for immunotherapy and even disease prevention. [Correction added on 24 January 2025, after first online publication: the third subtitle in Abstract section has been changed to ‘Results’.]</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta-Analysis 新型降糖药对2型糖尿病合并心血管疾病患者的心血管治疗益处:一项网络meta分析
IF 3 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-09 DOI: 10.1111/1753-0407.70044
Saixian Shi, Xiaofeng Li, Ye Chen, Jiahao Li, Yan Dai

Objective

Provide an evidence-based basis for the selection of cardiovascular benefit drugs in Type 2 diabetes mellitus (T2DM) patients with cardiovascular disease (CVD).

Methods

Conduct a comprehensive search of all relevant literature from PubMed, Embase, Web of Science, Cochrane Library, and Clinical Trials.gov from their establishment until December 13, 2023, and select randomized controlled trials (RCTs) that meet the pre-established inclusion and exclusion criteria. Use the Cochrane bias risk assessment tool to evaluate the quality of the included literature. Use R 4.3.2 software to conduct network meta-analysis for drug category comparison.

Results

A total of 24 large-scale randomized controlled trials (RCTs) were included, including 19 intervention measures, and 172 803 patients participated in the study. The results of the network meta-analysis show that: GLP1RA (OR 0.89, 95% CI 0.81–0.97) and SGLT2i (OR 0.91, 95% CI 0.83–0.99) can reduce the occurrence of major adverse cardiovascular events (MACE), GLP1RA (OR 0.88, 95% CI 0.79–0.97) and SGLT2i (OR 0.89, 95% CI 0.81–0.99) reduced the risk of cardiovascular death. SGLT2i (OR 0.68, 95% CI 0.62–0.75) reduced the occurrence of hospitalization for heart failure, GLP1RA (OR 0.88, 95% CI 0.81–0.97) and SGLT2i (OR 0.89, 95% CI 0.80–0.97) reduced the occurrence of all-cause death.

Conclusion

In the comparison of new hypoglycemic drug classes, GLP1RA and SGLT2i reduced MACE, cardiovascular mortality and all-cause mortality in T2DM patients with CVD, with no significant difference in efficacy, and DPP4i was noninferior to placebo. Only GLP1RA reduced the risk of nonfatal stroke, and only SGLT2i reduced the risk of HHF.

目的:为2型糖尿病(T2DM)合并心血管疾病(CVD)患者心血管获益药物的选择提供循证依据。方法:全面检索PubMed、Embase、Web of Science、Cochrane Library和Clinical trials .gov网站自成立至2023年12月13日的所有相关文献,并选择符合预先设定的纳入和排除标准的随机对照试验(RCTs)。使用Cochrane偏倚风险评估工具评价纳入文献的质量。使用r4.3.2软件进行网络meta分析,进行药品品类比较。结果:共纳入24项大规模随机对照试验(RCTs),包括19项干预措施,共纳入172 803例患者。网络荟萃分析结果显示:GLP1RA (OR 0.89, 95% CI 0.81-0.97)和SGLT2i (OR 0.91, 95% CI 0.83-0.99)可降低主要心血管不良事件(MACE)的发生,GLP1RA (OR 0.88, 95% CI 0.79-0.97)和SGLT2i (OR 0.89, 95% CI 0.81-0.99)可降低心血管死亡风险。SGLT2i (OR 0.68, 95% CI 0.62-0.75)降低了心力衰竭住院的发生率,GLP1RA (OR 0.88, 95% CI 0.81-0.97)和SGLT2i (OR 0.89, 95% CI 0.80-0.97)降低了全因死亡的发生率。结论:在新降糖药物类别的比较中,GLP1RA和SGLT2i降低T2DM合并CVD患者的MACE、心血管死亡率和全因死亡率,疗效无显著差异,且DPP4i不逊于安慰剂。只有GLP1RA降低了非致死性卒中的风险,只有SGLT2i降低了HHF的风险。
{"title":"Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta-Analysis","authors":"Saixian Shi,&nbsp;Xiaofeng Li,&nbsp;Ye Chen,&nbsp;Jiahao Li,&nbsp;Yan Dai","doi":"10.1111/1753-0407.70044","DOIUrl":"10.1111/1753-0407.70044","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Provide an evidence-based basis for the selection of cardiovascular benefit drugs in Type 2 diabetes mellitus (T2DM) patients with cardiovascular disease (CVD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Conduct a comprehensive search of all relevant literature from PubMed, Embase, Web of Science, Cochrane Library, and Clinical Trials.gov from their establishment until December 13, 2023, and select randomized controlled trials (RCTs) that meet the pre-established inclusion and exclusion criteria. Use the Cochrane bias risk assessment tool to evaluate the quality of the included literature. Use R 4.3.2 software to conduct network meta-analysis for drug category comparison.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 24 large-scale randomized controlled trials (RCTs) were included, including 19 intervention measures, and 172 803 patients participated in the study. The results of the network meta-analysis show that: GLP1RA (OR 0.89, 95% CI 0.81–0.97) and SGLT2i (OR 0.91, 95% CI 0.83–0.99) can reduce the occurrence of major adverse cardiovascular events (MACE), GLP1RA (OR 0.88, 95% CI 0.79–0.97) and SGLT2i (OR 0.89, 95% CI 0.81–0.99) reduced the risk of cardiovascular death. SGLT2i (OR 0.68, 95% CI 0.62–0.75) reduced the occurrence of hospitalization for heart failure, GLP1RA (OR 0.88, 95% CI 0.81–0.97) and SGLT2i (OR 0.89, 95% CI 0.80–0.97) reduced the occurrence of all-cause death.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In the comparison of new hypoglycemic drug classes, GLP1RA and SGLT2i reduced MACE, cardiovascular mortality and all-cause mortality in T2DM patients with CVD, with no significant difference in efficacy, and DPP4i was noninferior to placebo. Only GLP1RA reduced the risk of nonfatal stroke, and only SGLT2i reduced the risk of HHF.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global and Regional Burden of Type 2 Diabetes Mellitus Attributable to Low Physical Activity From 1990 to 2021 1990年至2021年低身体活动导致的全球和区域2型糖尿病负担
IF 3 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-06 DOI: 10.1111/1753-0407.70043
Lihang Yang, Diya Xie, Fengmin Liu, Jiaying Lin, Xin Lin, Yuquan Chen, Kun Zhang

Aim

Type 2 diabetes mellitus (T2DM) contributes to the heavy burden, but there lacks latest and comprehensive global research on the burden of T2DM attributable to low physical activity (LPA). This study aimed to quantify the global and regional burden of T2DM attributable to LPA from 1990 to 2021.

Methods

We utilized data including disability-adjusted life years (DALYs), mortality, age-standardized disability-adjusted life years (ASDR), and age-standardized mortality rates (ASMR) from the Global Burden of Disease (GBD) 2021. We assessed the burden across different ages, genders, and sociodemographic index (SDI). Joinpoint regression analysis was applied to estimated average annual percent change (AAPC).

Results

Between 1990 and 2021, DALYs and mortality of T2DM attributable to LPA increased rapidly. There was an increase in the ASDR and ASMR, with AAPC of 1.09 (95% CI: 1.03–1.16) and 0.32 (95% CI: 0.2–0.43), which was increased faster in males. Low-middle SDI countries have the highest ASDR and highest ASMR. The global PAF for ASDR and ASMR in 2021 is 7.38% and 9.45%. A U-shaped drift pattern was observed in most SDI quintiles in APC model. Population growth is a major contributor to the burden of T2DM, especially in countries with low SDI. Epidemiological changes also play an important role in DALYs and mortality. A negative correlation existed between SDI and both ASMR and ASDR.

Conclusion

Between 1990 and 2021, there was a marked rise in the global burden of T2DM associated with LPA. The findings lay the groundwork for informed decision-making a public health and healthcare delivery.

目的:2型糖尿病(T2DM)是加重负担的原因之一,但目前全球缺乏关于低体力活动(LPA)导致的T2DM负担的最新、全面的研究。本研究旨在量化1990年至2021年由LPA引起的全球和区域T2DM负担。方法:我们使用来自2021年全球疾病负担(GBD)的数据,包括残疾调整生命年(DALYs)、死亡率、年龄标准化残疾调整生命年(ASDR)和年龄标准化死亡率(ASMR)。我们评估了不同年龄、性别和社会人口指数(SDI)的负担。采用联合点回归分析估计平均年变化百分数(AAPC)。结果:1990 - 2021年间,LPA导致的T2DM DALYs和死亡率迅速上升。ASDR和ASMR增加,AAPC分别为1.09 (95% CI: 1.03-1.16)和0.32 (95% CI: 0.2-0.43),其中男性增加更快。中低SDI国家的ASDR和ASMR最高。2021年ASDR和ASMR的全球PAF分别为7.38%和9.45%。在APC模型中,大部分SDI五分位数呈u型漂移。人口增长是2型糖尿病负担的主要因素,特别是在低SDI国家。流行病学变化在伤残调整生命年和死亡率中也起着重要作用。SDI与ASMR、ASDR均呈负相关。结论:1990年至2021年间,与LPA相关的T2DM全球负担显著增加。这些发现为公共卫生和医疗保健服务的知情决策奠定了基础。
{"title":"Global and Regional Burden of Type 2 Diabetes Mellitus Attributable to Low Physical Activity From 1990 to 2021","authors":"Lihang Yang,&nbsp;Diya Xie,&nbsp;Fengmin Liu,&nbsp;Jiaying Lin,&nbsp;Xin Lin,&nbsp;Yuquan Chen,&nbsp;Kun Zhang","doi":"10.1111/1753-0407.70043","DOIUrl":"10.1111/1753-0407.70043","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Type 2 diabetes mellitus (T2DM) contributes to the heavy burden, but there lacks latest and comprehensive global research on the burden of T2DM attributable to low physical activity (LPA). This study aimed to quantify the global and regional burden of T2DM attributable to LPA from 1990 to 2021.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We utilized data including disability-adjusted life years (DALYs), mortality, age-standardized disability-adjusted life years (ASDR), and age-standardized mortality rates (ASMR) from the Global Burden of Disease (GBD) 2021. We assessed the burden across different ages, genders, and sociodemographic index (SDI). Joinpoint regression analysis was applied to estimated average annual percent change (AAPC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Between 1990 and 2021, DALYs and mortality of T2DM attributable to LPA increased rapidly. There was an increase in the ASDR and ASMR, with AAPC of 1.09 (95% CI: 1.03–1.16) and 0.32 (95% CI: 0.2–0.43), which was increased faster in males. Low-middle SDI countries have the highest ASDR and highest ASMR. The global PAF for ASDR and ASMR in 2021 is 7.38% and 9.45%. A U-shaped drift pattern was observed in most SDI quintiles in APC model. Population growth is a major contributor to the burden of T2DM, especially in countries with low SDI. Epidemiological changes also play an important role in DALYs and mortality. A negative correlation existed between SDI and both ASMR and ASDR.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Between 1990 and 2021, there was a marked rise in the global burden of T2DM associated with LPA. The findings lay the groundwork for informed decision-making a public health and healthcare delivery.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11702482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Diabetes
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1